Communiqués ATTANA AB Börse Stuttgart

Actions

SE0010547273

Recherche biotechnologique et médicale

Cours en clôture Börse Stuttgart			Varia. 5j.	Varia. 1 janv.
- ^EUR	-.--%		-.--%	-

28/08	Attana AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
01/06	Attana AB (publ) publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

30/04/24	BioInvent evaluating Attana Technology	AQ
25/04/24	Attana enters the third year of a five-year service and support contract with a leading health institute in the US	AQ
01/04/24	New paper using Attana tecnology to understand how viruses enter human cells	AQ
05/03/24	One of US leading health institutes has placed an order for an upgrade of an existing instrument, valued at $150k	AQ
13/02/24	New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.	AQ
23/01/24	New publication using Attana technology towards environmentally friendly and financially viable methods to create functional materials	AQ
20/12/23	New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases	AQ
18/12/23	Biosensors to characterize immune response to bacterial diseases	AQ
05/12/23	Attana and Linnaeus University have published the first part of the science behind immunity profiles	AQ
04/12/23	Breakthrough order with new customer in the USA	AQ
23/11/23	Strengthened collaboration with European biotech customer who extends their service and support agreement for another 12 months.	AQ
20/11/23	A new publication using Attana Technology from National University of Singapore examining the neutralization capacity of human IgG antibodies agsinst different mutations of the SARS-CoV-2	AQ
15/11/23	Robust QCM-Based Sensing and Assay Formats in Commercialized Systems	AQ
04/10/23	Dear shareholders and valuable followers,	AQ
26/09/23	New publication that shows the strength of Attana's offering in diagnostics, here applied in veterinary medicine.	AQ
06/09/23	New publication from National University of Singapore using Attana Technology to study Immune Response from Tuberculosis Exposed Healthy Individuals	AQ
28/08/23	The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.	AQ
30/05/23	Education in advanced Attana cell-based assays and practical hands-on training in maintenance.	AQ
23/05/23	Attana prolongs service and support contract with European client	AQ
23/05/23	Attanas immunity profiles depicted in the Life Science section of yesterday's Dagens Nyheter	AQ
03/05/23	Attana and Mario Negri Research Institute have signed a research agreement	AQ
18/04/23	Attana enters the second year of a five-year service and support contract with a leading health institute in the US	AQ
14/02/23	Attana has submitted an international patent application (PCT)	AQ
02/02/23	Attana and 19 Plus AB (Testmottagningen.se by Zample) sign collaboration agreement of marketing and sales of Attana individual immunity profiles	AQ
27/12/22	Reversible sensor chips for real-time determination of protein- carbohydrate interactions on living cancer cells for the diagnosis and treatment of cancer	AQ